Tamoxifen citrate and Skin hyperpigmentation - a phase IV clinical study of FDA data

Summary:

Skin hyperpigmentation is found among people who take Tamoxifen citrate, especially for people who are female, 40-49 old.

The phase IV clinical study analyzes which people take Tamoxifen citrate and have Skin hyperpigmentation. It is created by eHealthMe based on reports of 10,213 people who have side effects when taking Tamoxifen citrate from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Feb, 07, 2023

10,213 people reported to have side effects when taking Tamoxifen citrate.
Among them, 25 people (0.24%) have Skin hyperpigmentation.

What is Tamoxifen citrate?

Tamoxifen citrate has active ingredients of tamoxifen citrate. It is often used in breast cancer. eHealthMe is studying from 11,378 Tamoxifen citrate users for its effectiveness, alternative drugs and more.

What is Skin hyperpigmentation?

Skin hyperpigmentation (disorders affect the colour of your skin) is found to be associated with 1,353 drugs and 789 conditions by eHealthMe.

Number of Tamoxifen citrate and Skin hyperpigmentation reports submitted per year:

Could Tamoxifen citrate cause Skin hyperpigmentation?

Gender of people who have Skin hyperpigmentation when taking Tamoxifen citrate *:

female: 100 %
male: 0.0 %

Age of people who have Skin hyperpigmentation when taking Tamoxifen citrate *:

Common drugs people take besides Tamoxifen citrate *:

Common side effects people have besides Skin hyperpigmentation *:

Bone Disorder: 22 people, 88.00%
Pain In Jaw: 22 people, 88.00%
Stress And Anxiety: 22 people, 88.00%
Pain: 22 people, 88.00%
Fever: 19 people, 76.00%
Osteonecrosis Of Jaw (death of bone of jaw): 18 people, 72.00%
General Physical Health Deterioration (weak health status): 15 people, 60.00%
Rashes (redness): 15 people, 60.00%
Positron Emission Tomogram Abnormal: 15 people, 60.00%
Gingival Infection (gum infection): 15 people, 60.00%

Common conditions people have *:

Metastases To Bone (cancer spreads to bone): 15 people, 60.00%
Stress And Anxiety: 12 people, 48.00%
Sleep Disorder: 12 people, 48.00%
Neoplasm Malignant (cancer tumour): 12 people, 48.00%
Depression: 12 people, 48.00%
Breast Cancer Metastatic: 8 people, 32.00%
Pain: 7 people, 28.00%
Glaucoma (increased fluid pressure in the eye with vision loss): 1 person, 4.00%

* Approximation only. Some reports may have incomplete information.

Do you take Tamoxifen citrate and have Skin hyperpigmentation?

Check whether Skin hyperpigmentation is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related publications that referenced our studies

K?rm?z?bekmez H, Yesiltepe Mutlu RG, Dursun F, ??güven ?P, "Tamoxifen-associated hirsutism: an unusual side effect in a 5-year-old girl with McCune-Albright syndrome", Journal of Pediatric Endocrinology and Metabolism, 2015 Sep .

Related studies

Browse all side effects of Tamoxifen citrate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Skin hyperpigmentation treatments and more:

Skin hyperpigmentation (10,564 reports)

COVID vaccines that are related to Skin hyperpigmentation:

Common drugs associated with Skin hyperpigmentation:

All the drugs that are associated with Skin hyperpigmentation:

Skin hyperpigmentation (1,353 drugs)

Common conditions associated with Skin hyperpigmentation:

Acne: 1,803 reports
Birth control: 296 reports
High blood pressure: 188 reports
Multiple myeloma: 155 reports
Pain: 126 reports

All the conditions that are associated with Skin hyperpigmentation:

Skin hyperpigmentation (789 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on tamoxifen citrate (the active ingredients of Tamoxifen citrate) and Tamoxifen citrate (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.